SCHEMBL572809

SCHEMBL572809

CCCCCc1cc(C)ccc1O

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TYR P14679 3/20 0.56
ALOX15 P16050 2/20 0.53
TP53 P04637 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
HTT P42858 2/20 0.53
MEN1 O00255 1/20 0.53
CYP3A4 P08684 1/20 0.53
ALOX5 P09917 1/20 0.53
MAPT P10636 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.53
AMY1A P0DUB6 1/20 0.52
IGF1R P08069 1/20 0.46
TRPA1 O75762 1/20 0.45
BID P55957 3/20 0.42
MCL1 Q07820 3/20 0.42
KAT8 Q9H7Z6 3/20 0.42
BCL2L1 Q07817 2/20 0.42
BAK1 Q16611 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27689409 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL9504207 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL27313251 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL2822413 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL29481001 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL1021853 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL361376 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL1023146 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL1712206 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT
SCHEMBL7206463 0.98 TYR (0.59) TYRALOX15TP53TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10463623-B2 Compositions exhibiting delayed transit through the gastrointestinal tract RUBICON RESEARCH PRIVATE LIMITED (IN) 2019-11-05 US claimed
EP-2346351-B1 COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT RUBICON RES PRIVATE LIMITED (IN) 2019-07-03 EP claimed
CN-105051219-B heat treatment oil composition 出光兴产株式会社 2017-09-12 CN claimed
US-20110229569-A1 COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT RUBICON RESEARCH PRIVATE LIMITED (IN) 2011-09-22 US claimed
EP-2346351-A2 COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT Rubicon Research Private Limited (IN) 2011-07-27 EP claimed
WO-2010038237-A2 COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT RUBICON RESEARCH PRIVATE LIMITED (IN) 2010-04-08 WO claimed
US-12377194-B2 JAB1 inhibitory compositions for ossification and methods related thereto EMORY UNIVERSITY (US) 2025-08-05 US disclosed
US-20250059512-A1 TISSUE PROCESSING APPARATUS AND METHOD FOR INFUSING BIOACTIVE AGENTS INTO TISSUE WARSAW ORTHOPEDIC, INC (US) 2025-02-20 US disclosed
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-12-26 US disclosed
US-12134783-B2 Tissue processing apparatus and method for infusing bioactive agents into tissue WARSAW ORTHOPEDIC, INC. (US) 2024-11-05 US disclosed
EP-4431490-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUNDS, METHOD FOR PRODUCING CARBAMATE COMPOUNDS, METHOD FOR RECOVERING AMINE COMPOUNDS, AND ISOCYANATE COMPOSITION Asahi Kasei Kabushiki Kaisha (JP) 2024-09-18 EP disclosed
EP-4431491-A1 CARBONYL COMPOUND, METHOD FOR PRODUCING CARBONYL COMPOUND, METHOD FOR PRODUCING ISOCYANATE COMPOUND, AND ISOCYANATE COMPOSITION Asahi Kasei Kabushiki Kaisha (JP) 2024-09-18 EP disclosed
CN-118302407-A Carbonyl compound, method for producing isocyanate compound, and isocyanate composition 旭化成株式会社 2024-07-05 CN disclosed
EP-0754061-A1 NEW ORAL PHARMACEUTICAL DOSAGE FORM Astra Aktiebolag (SE) 1997-01-22 EP disclosed
WO-1996024375-A1 NEW ORAL PHARMACEUTICAL DOSAGE FORM ASTRA AKTIEBOLAG (SE) 1996-08-15 WO disclosed
WO-1994000112-A1 AN ORAL FORMULATION FOR GASTRIC ANTIBACTERIAL TREATMENT AS WELL AS A PROCESS THEREOF AND THE USE ASTRA AKTIEBOLAG (SE) 1994-01-06 WO disclosed
EP-0214102-B1 5-ARALKYL-SUBSTITUTED 2H-BENZOTRIAZOLES AND STABILIZED COMPOSITIONS CIBA-GEIGY AG (CH) 1990-05-23 EP disclosed
EP-0235077-A2 Curable mixtures based on diglycidyl compounds and metal complexes CIBA-GEIGY AG (CH) 1987-09-02 EP disclosed
US-3979309-A Lubricating oil additive UOP INC. (US) 1976-09-07 US disclosed
US-3946086-A Method of producing 2,6-dialkyl- and 2,6-diaralkyl-substituted derivatives of p-cresol GERSHANOV FELIX BORISOVICH 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION IDH3A, CA7, C9 TYR 833/4885ALOX15 1785/4885TP53 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.